Key Highlights

  • BYSI was up 14.00 percent to USD 0.7339 in pre-market trading on November 2, 2026.
  • No company announcement dated late October to November 2, 2026 was identified as a catalyst.
  • Cash and short-term investments from continuing operations were USD 6.5 million as of June 30, 2026.
  • The company reported a net loss of USD 12.4 million for the first six months of 2026.
  • The confirmatory DUBLIN-4 Phase 3 trial plans to enroll 442 patients.

What moved BeyondSpring shares before the open

BeyondSpring (NASDAQ:BYSI) was up 14.00 percent to USD 0.7339 in pre-market trading on November 2, 2026. The move came without a company press release or regulatory filing that this review could identify for the period from late October through November 2, 2026.

Without a stated trigger, the jump looks consistent with the trading pattern of a small-cap biotech priced below USD 1. Shares in that group often move sharply on thin volume, and sentiment around clinical-stage oncology names can shift without any new disclosure from the company itself.

Latest company updates

The most recent Leadership news came in a company press release dated June 4, 2026. Min Qiu became chief executive and Na Li became chief financial officer, effective July 1, 2026, while Dr. Lan Huang stays as chairman. The company said its priority is executing DUBLIN-4.

DUBLIN-4 is a confirmatory Phase 3 study of plinabulin plus docetaxel in non-squamous, EGFR wild-type non-small cell lung cancer after prior PD-1 or PD-L1 inhibitor therapy. Planned enrollment is 442 patients, randomized one to one.

Business background and results

BeyondSpring is a clinical-stage biopharmaceutical company based in Florham Park, New Jersey, developing first-in-class cancer therapies. Plinabulin is described by the company as a GEF-H1 agonist, and over 700 patients have received it in clinical programs.

In the DUBLIN-3 Phase 3 study, published in 2024, the company reported that adding plinabulin to docetaxel doubled two-year and three-year survival rates and cut grade 4 neutropenia from 33 percent to 5 percent. The company also holds an Equity stake in SEED Therapeutics, a protein degradation company with large pharmaceutical collaborations.

Balance sheet and risk

Based on a report dated August 14, 2026, cash and short-term investments from continuing operations were USD 6.5 million as of June 30, 2026, against a net loss of USD 12.4 million for the first six months of the year. Dividing the cash by half-year loss gives roughly 3 months of coverage at that pace (calculated), which suggests further funding will be needed.

Penny stocks carry elevated volatility, thin Liquidity and a risk of dilution if new shares are issued to raise capital. Pre-market prices can also differ sharply from regular-session trading.

What to watch next

Investors will look for any DUBLIN-4 enrollment or site activation update, along with financing or Partnership news from the company. Filings with the SEC and the next Quarterly Report will show whether the cash position has changed since June 30, 2026.